Table 2.
Summary of the estimated population pharmacokinetic parameters from both base and covariate models
| Base Model | Covariate Model | ||||
|---|---|---|---|---|---|
|
| |||||
| Parameter (Unit) | Population mean | BSV% | Population mean | BSV% | |
| Efavirenz | |||||
| Ka (h−1) | 2.21 | 88 | 2.25 | 90 | |
| tlag (h) | 0.893 | 61 | 0.902 | 58 | |
| Vc (L) | 107 | 31 | 106 | 31 | |
| VP (L) | 304 | 21 | 299 | 26 | |
| Q (L/h) | 17.1 | 36 | 17.1 | 38 | |
| CLother/F (L/h) | 0.11 | 8.1 | 0.12 | 7.6 | |
| (CLf1/F)M1 (L/h) | 0.99 | 11 | 0.89 | 5.7 | |
| (CLf2/F) (L/h) | 2.4 | 42 | CYP2B6 *1*1 | 3.04 | 20 |
| CYP2B6 *1*6 | 2.91 | ||||
| CYP2B6 *1*1 | 1.63 | ||||
| 7-hydroxyefavirenz | |||||
| Vm1 (L) | 10* | --- | 10* | --- | |
| CLm1 (L/h) | 11.9 | 6.5 | 12.1 | 8.1 | |
| 8-hydroxyefavirenz | |||||
| Vm2 (L) | 10* | --- | 10* | --- | |
| CLm2 (L/h) | 6.24 | 12 | 6.12 | 12 | |
| Clopidogrel Effect | |||||
| INH1 | 0.778 | 0.780 | --- | ||
| INH2 | 0.812 | 0.812 | --- | ||
*
Vm1 and Vm2 were fixed to 10 L